NasdaqCM - Nasdaq Real Time Price ? USD
ASLAN Pharmaceuticals Limited (ASLN)
At close: July 18 at 4:00 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -3.6 | -3.76 | -26.72 | -18.8 |
| Low Estimate | -3.6 | -3.76 | -26.72 | -18.8 |
| High Estimate | -3.6 | -3.76 | -26.72 | -18.8 |
| Year Ago EPS | -0.88 | -4.48 | -21.52 | -26.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | 12M | -- | 12M | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -6.4 | -6.24 | -5.2 | -4.88 |
| EPS Actual | -0.88 | -4.48 | -6.24 | -4.24 |
| Difference | 5.52 | 1.76 | -1.04 | 0.64 |
| Surprise % | 86.20% | 28.20% | -20.00% | 13.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -3.6 | -3.76 | -26.72 | -18.8 |
| 7 Days Ago | -3.6 | -3.76 | -26.72 | -18.8 |
| 30 Days Ago | -0.45 | -0.47 | -3.34 | -2.35 |
| 60 Days Ago | -0.45 | -0.47 | -3.34 | -2.35 |
| 90 Days Ago | -0.54 | -0.53 | -3.62 | -2.42 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ASLN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -309.10% | -- | -- | 5.50% |
| Next Qtr. | 16.10% | -- | -- | 9.60% |
| Current Year | -24.20% | -- | -- | 2.80% |
| Next Year | 29.60% | -- | -- | 12.90% |
| Next 5 Years (per annum) | -- | -- | -- | 11.83% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/15/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/18/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 3/13/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/11/2024 |
Related Tickers
CYYNF Cynata Therapeutics Limited
0.1900
0.00%
MLLCF Molecular Partners AG
5.89
0.00%
ALMS Alumis Inc.
11.96
+1.53%
HSTC HST Global, Inc.
1.0200
0.00%
AKBLF ALK-Abelló A/S
24.60
0.00%
TCON TRACON Pharmaceuticals, Inc.
0.0571
-14.78%
SYRE Spyre Therapeutics, Inc.
27.96
-0.29%
THRD Third Harmonic Bio, Inc.
12.00
+0.67%
AKESF Akeso, Inc.
5.68
0.00%
CNTB Connect Biopharma Holdings Limited
1.2500
+9.65%